CTOs on the Move

Macrocure

www.macrocure.com

 
Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body`s own wound healing and regenerative components directly into the wound itself.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.macrocure.com
  • Radnor Financial Center, Suite F200 150 North Radnor Road
    Radnor, PA USA 19087
  • Phone: 201.620.6640

Executives

Name Title Contact Details

Similar Companies

Kowa Pharmaceuticals America

Kowa Pharmaceuticals America is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Success TMS

Get relief from depression in under 8 weeks. Safe & FDA approved. Covered by Insurance & Medicare. Get your FREE consultation. Book an appointment Today!

Brighton Pharmaceuticals

Brighton Pharmaceuticals is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignite Mental Health

Join us in the fight to end the mental health crisis plaguing our campuses and transform the future of mental health.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.